AbbVievsCorcept Therapeutics

ABBV and CORT stock compared: price, dividend, valuation and results, from SEC filings.

CORT

Corcept Therapeutics Incorporated

$72.94

Value $7.8B

-1.04%
CORT's page

AbbVie (ABBV) has a market value of $522B and Corcept Therapeutics (CORT) $7.8B. Over the last year, with dividends, ABBV moved +30.3% and CORT -7.0%. The P/E is 50.7 for ABBV and 48.7 for CORT. Dividend yield: ABBV 2.35%, CORT none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    ABBV$522B

    CORT$7.8B

    ABBV is 67 times CORT

  • Revenue, 12 months

    ABBV$66.0B

    CORT$964M

    ABBV is 69 times CORT

  • Net income, 12 months

    ABBV$10.3B

    CORT$162M

    ABBV is 64 times CORT

  • Operating margin

    ABBV32.2%

    CORT11.5%

    20.7 points apart

  • ROIC

    ABBV25.7%

    CORT12.7%

    13.0 points apart

  • P/E

    ABBV50.7

    CORT48.7

    About the same

  • Dividend yield

    ABBV2.4%

    CORT0.0%

    2.4 points apart

  • 5-year return

    ABBV+201.5%

    CORT+217.1%

    15.6 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

ABBV+201.5%

CORT+217.1%

20040020222023202420252026
Returns by period
PeriodABBVWith dividendsCORTWith dividends
1 year since November 12, 2025+30.3%Price +26.5%-7.0%Price -7.0%
3 years since November 13, 2023+135.3%+33.0% a yearPrice +112.8%+193.9%+43.2% a yearPrice +193.9%
5 years since November 12, 2021+201.5%+24.7% a yearPrice +152.2%+217.1%+26.0% a yearPrice +217.1%
10 years since November 15, 2016+605.5%+21.6% a yearPrice +369.3%+667.0%+22.6% a yearPrice +667.0%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

ABBVAbbVieCORTCorcept Therapeutics

Valuation

ABBVCORT
Valuation
Price$295.03$72.94
Market value$522B$7.8B
Enterprise value (EV)$592B$7.4B
P/E50.748.7
P/E, 5-year median57.034.6
P/B–9.3
EV/EBIT27.966.6
Free cash flow yield3.6%2.5%

Results and growth

ABBVCORT
Results and growth
Revenue, 12 months$66.0B$964M
Net income, 12 months$10.3B$162M
Free cash flow, 12 months$18.9B$195M
Earnings per share, 12 months$5.81$1.50
Revenue growth, year on year8.6%12.8%
Revenue growth a year, past+5.9%over 5 years+16.6%over 5 years
EPS growth a year, past-2.8%over 5 years-0.7%over 5 years

Margins and returns on capital

ABBVCORT
Margins and returns on capital
Gross margin73.7%98.5%
Operating margin32.2%11.5%
Net margin15.7%16.8%
ROIC25.7%12.7%
ROE–23.5%

Balance sheet

ABBVCORT
Balance sheet
Cash$10.8B$371M
Total debt$80.9B$9.0M
Net debt / EBITDA3.2-3.3
Interest cover7.1×–

Dividends and buybacks

ABBVCORT
Dividends and buybacks
Dividend yield2.4%–
Dividend per share, 12 months$6.92–
Dividend growth a year, past+6.6%over 5 years–
Buyback yield0.2%2.2%
Shareholder yield2.5%2.2%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: ABBV or CORT

Didn't find what you were looking for?

Ask us
Which is bigger, AbbVie or Corcept Therapeutics?

By market value, AbbVie ($522B) is about 67.2 times Corcept Therapeutics ($7.8B), at today's prices.

How did ABBV and CORT stock do over the last 10 years?

Since November 15, 2016, ABBV's price moved +369.3% and CORT's +667.0%. With dividends: ABBV +605.5% (+21.6% a year), CORT +667.0% (+22.6% a year). Past returns do not predict future ones.

Which pays the higher dividend, ABBV or CORT?

The dividend yield at today's price is 2.35% for AbbVie and none for Corcept Therapeutics. Over the last twelve months they paid $6.92 and – per share.

What is the P/E of ABBV and CORT?

At today's price, the P/E is 50.7 for ABBV and 48.7 for CORT. The median of the last five years was 57.0 and 34.6, which shows where each stands against its own past.

Which has the higher profit margins, AbbVie or Corcept Therapeutics?

Over the last twelve months, the net margin was 15.7% for AbbVie and 16.8% for Corcept Therapeutics, and the operating margin 32.2% and 11.5%. Revenue was $66.0B and $964M.

Which is the better investment, AbbVie or Corcept Therapeutics?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.